Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Company expects strong organic growth in sales, EBITDA in 2022
Serina has over 17 years of experience in the biopharmaceutical industry
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Collaboration in the industry needs to be institutionalised to drive the growth.
Subscribe To Our Newsletter & Stay Updated
